ArticleLupus science & medicine2018
QRISK3 improves detection of cardiovascular disease risk in patients with systemic lupus erythematosus.
Article in Lupus science & medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Cardiovascular Involvement in Systemic Lupus Erythematosus: Focus on Arrhythmias.Diagnostics (Basel, Switzerland) · 2026Review
- Perivascular pathology, not macrovascular complexity, governs glymphatic-related dysfunction in preclinical cerebral small vessel disease.Scientific reports · 2026Article
- Divergence in Estimated Risks and Actual Rates of Atherosclerotic Cardiovascular Events and their Management in a Longitudinal Cohort of Patients with Dermatomyositis with Skin Involvement.JID innovations : skin science from molecules to population health · 2025Article
- Association Between Cardiovascular Risk and Subclinical Atherosclerosis in Korean Female Patients with Systemic Lupus Erythematosus.Journal of clinical medicine · 2025Article
- Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus.Seminars in arthritis and rheumatism · 2024Article
- Accumulation of Microvascular Target Organ Damage in Systemic Lupus Erythematosus Patients Is Associated with Increased Cardiovascular Risk.Journal of clinical medicine · 2024Article
- State of current management of the heightened risk for atherosclerotic cardiovascular events in an established cohort of patients with lupus erythematosus.Lupus science & medicine · 2023Article
- Subclinical Carotid Atherosclerosis in Patients with Rheumatoid Arthritis at Low Cardiovascular Risk.Biomedicines · 2023Article
- Generic and disease-adapted cardiovascular risk scores as predictors of atherosclerosis progression in SLE.Lupus science & medicine · 2023Article
- Lupus nephropathy beyond immunosuppression: Searching for nephro and cardioprotection.Frontiers in nephrology · 2023Review
- Cardiovascular Outcomes in Systemic Lupus Erythematosus.Current cardiology reports · 2022Review
- Assessing the validity of QRISK3 in predicting cardiovascular events in systemic lupus erythematosus.Lupus science & medicine · 2022Article
- QRISK3-based analysis of cardiovascular risk factors in patients with long-term but well-controlled systemic lupus erythematosus.American journal of translational research · 2022Article
- Challenges in Implementing Cardiovascular Risk Scores for Assessment of Young People With Childhood-Onset Autoimmune Rheumatic Conditions.Frontiers in medicine · 2022Article
- Assessment and management of the heightened risk for atherosclerotic cardiovascular events in patients with lupus erythematosus or dermatomyositis.International journal of women's dermatology · 2021Review
- Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Role of Fibroblast Growth Factor 23- Phosphate Axis.International journal of nephrology and renovascular disease · 2021Article
- Systemic Lupus Erythematosus, Its Impact on Selected Cardiovascular Risk Factors, and Correlation with Duration of Illness: A Pilot Study.Cardiology research and practice · 2020Article
- Cardiometabolic Risk, Evaluation, and Control in Lupus Nephritis.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objective10-year cardiovascular disease (CVD) risk scores are calculated using algorithms, including Framingham (worldwide) and QRISK2 (UK). Recently, an updated QRISK3 model was introduced, which considers new variables including SLE and steroid prescription, not included in QRISK2 and Framingham algorithms. We sought to determine the extent to which QRISK3 improves identification of high-risk patients with SLE and whether the score relates to standard and novel markers of SLE-specific endothelial dysfunction.
methodsFramingham and QRISK2/3 scores were calculated in patients with SLE (n=109) and healthy controls (n=29) using clinical measures. In a smaller cohort (n=58), markers of inflammation and endothelial dysfunction, including CD144
resultsPatients with SLE demonstrated significantly higher QRISK3 scores than controls (5.0%vs0.3%, p<0.001). 21/109 patients with SLE (19%) and 24/109(22%) were newly identified as being at high risk of a CV event when using QRISK3 versus QRISK2 (29vs8patients) and QRISK3 versus Framingham (29vs5patients; p<0.001), respectively. These 'new QRISK3' patients with SLE were more likely to have lupus nephritis, be anticardiolipin antibody positive, currently prescribed corticosteroids, had a higher Body Mass Index and systolic blood pressure (BP) than low-risk patients with SLE. Rates of antiplatelet (8/21) and statin use (5/21) were low in the new QRISK3 group. EMVs, hsCRP and triglyceride levels were significantly higher in new QRISK3 patientscompared with low-risk patients with SLE (p<0.05). Furthermore, pulse wave velocity and VCAM were significantly elevated in all high versus low QRISK3 patients.
conclusionsQRISK3 captures significantly more patients with SLE with an elevated 10-year risk of developing CVD, which is associated with measures of endothelial dysfunction; EMVs and systolic BP. The adoption of QRISK3 will enhance management of CVD risk in patients with SLE for improved outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.